Last reviewed · How we verify
Oncoquest-CLL vaccine
At a glance
| Generic name | Oncoquest-CLL vaccine |
|---|---|
| Also known as | ATCE Vaccine, ATCEV, Autologous Tumor Vaccine, Oncoquest-CLL |
| Sponsor | XEME Biopharma Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oncoquest-CLL vaccine CI brief — competitive landscape report
- Oncoquest-CLL vaccine updates RSS · CI watch RSS
- XEME Biopharma Inc. portfolio CI